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INTRODUCTION: Limb-girdle muscular dystrophy presents with heterogeneous clinical and molecular features. The
primary characteristic of this disorder is proximal muscular weakness with variable age of onset, speed of
progression, and intensity of symptoms. Sarcoglycanopathies, which are a subgroup of the limb-girdle muscular
dystrophies, are caused by mutations in sarcoglycan genes. Mutations in these genes cause secondary deficiencies in
other proteins, due to the instability of the dystrophin-glycoprotein complex. Therefore, determining the etiology
of a given sarcoglycanopathy requires costly and occasionally inaccessible molecular methods.
OBJECTIVE: The aim of this study was to identify phenotypic differences among limb-girdle muscular dystrophy
patients who were grouped according to the immunohistochemical phenotypes for the four sarcoglycans.
METHODS: To identify phenotypic differences among patients with different types of sarcoglycanopathies, a
questionnaire was used and the muscle strength and range of motion of nine joints in 45 patients recruited from the
Department of Neurology – HC-FMUSP (Clinics Hospital of the Faculty of Medicine of the University of Sa˜o Paulo)
were evaluated. The findings obtained from these analyses were compared with the results of the
immunohistochemical findings.
RESULTS: The patients were divided into the following groups based on the immunohistochemical findings: a-
sarcoglycanopathies (16 patients), b-sarcoglycanopathies (1 patient), c-sarcoglycanopathies (5 patients), and non-
sarcoglycanopathies (23 patients). The muscle strength analysis revealed significant differences for both upper and
lower limb muscles, particularly the shoulder and hip muscles, as expected. No pattern of joint contractures was
found among the four groups analyzed, even within the same family. However, a high frequency of tiptoe gait was
observed in patients with a-sarcoglycanopathies, while calf pseudo-hypertrophy was most common in patients with
non-sarcoglycanopathies. The a-sarcoglycanopathy patients presented with more severe muscle weakness than did
c-sarcoglycanopathy patients.
CONCLUSION: The clinical differences observed in this study, which were associated with the immunohistochemical
findings, may help to prioritize the mutational investigation of sarcoglycan genes.
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INTRODUCTION
Muscular dystrophy is a necrotic degenerative/regenera-
tive process of the muscles and results in progressive
muscle weakness and wasting. The mechanisms by which
various molecular defects result in muscular dystrophy are
not yet fully understood.1
Limb-girdle muscular dystrophies (LGMD) are clearly
distinct from other muscular disorders, such as dystrophino-
pathies, myotonic disorders, or facioscapulohumeral dystro-
phies.2 The clinical course of LGMD is characterized by normal
intelligence and great variability in muscle weakness and
wasting, ranging frommild to severe forms. LGMDmay show
an early onset in the first decade of life with rapid disease
progression or a later onset with slower disease progression.1,3
Hyperlordosis,4 scapular winging (escapula alata),5,6 tendon
contractures,7 and a tiptoe gait pattern4 with a wide-based
stance7 are associated with this disease. Serum creatine kinase
(CK) levels are elevated in most cases, and patients may
develop cardiomyopathies and/or respiratory insufficiencies.6
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Due to the heterogeneity of LGMD and the lack of
diagnostic specificity, estimates of the prevalence of all
forms of LGMD range from 1/14,500 to 1/123,000.2
Autosomal dominant LGMD is relatively rare (5 loci
described),8 but cases of autosomal recessive LGMD have
been characterized worldwide and are a heterogeneous
group of disorders that lead to progressive muscle wasting
and weakness. Current evidence suggests the involvement
of at least 14 distinct loci in autosomal recessive LGMD
(http://www.musclegenetable.org).9
LGMD2C – F are autosomal recessive LGMDs, also known
as sarcoglycanopathies (SGP), which are caused bymutations
in the genes encoding the c-, a-, b-, and d-sarcoglycan
proteins (SG), respectively.10-13 The SGs are glycosylated
proteins with single transmembrane domains,14 and correct
assembly of the sarcoglycan complex is required for the
maintenance of the sarcolemma.15,16 Together with sarco-
span, dystrophin, dystroglycans, syntrophins, and a-dystro-
brevin, the SGs constitute the dystrophin-glycoprotein
complex (DGC).17 The DGC acts as a link between the
muscle cell cytoskeleton and the extracellular matrix,
providing mechanical support for the plasma membrane
during myofiber contraction.14,18 The function of the SGs is
not fully understood, but they appear to play both mechan-
ical and non-mechanical roles that mediate interactions
among the extracellular matrix, the sarcolemma and the
cytoskeleton.19,20 A primary mutation in any one of the
sarcoglycan genes (a, b, c or d) can lead to the total or partial
loss of that sarcoglycan, secondary deficiencies of the other
sarcoglycans and the occasional reduction of dystrophin
labeling in muscle tissue.21 Inter- and intra-familial hetero-
geneity is frequent.22 Mutations in the gene for a-sarcoglycan
are the most common sarcoglycan mutations, whereas
mutations in d-sarcoglycan are the rarest.23
The phenotypes of the sarcoglycanopathies overlap with
the dystrophinopathieswith the important distinction that the
learning disability specifically associated with Duchenne’s is
not present, and scapular winging is more frequent in
SGPs.6,9,22,24
Some studies have shown distinct patterns of sarcoglycan
expression and labeling in various SGPs,1,14,16,24 but we
believe that further studies are required to obtain more
conclusive information because the characteristics of each
population vary greatly.
OBJECTIVES
The purpose of this study was to identify phenotypic
differences among LGMD patients who were grouped
according to the immunohistochemical findings for the four
sarcoglycans.
MATERIALS AND METHODS
Patients. Forty-five patients (from 40 families) with
clinical diagnoses of LGMD from the Department of
Neurology – HC-FMUSP were studied. The clinical
diagnosis was based on the presence of limb-girdle muscle
weakness, muscle retractions, myopathic alterations
determined by electromyography (EMG) and altered levels
of serum creatine kinase (CK). In all of the patients included in
this study, the diagnosis of dystrophinopathy was previously
excluded by mutational analysis using the multiple
polymerase chain reaction (PCR) method and protein
analysis by immunohistochemistry and western blotting.
This study was approved by the Institutional Review Board
Ethics Committee on Human Experimentation of the Clinics
Hospital of the University of Sa˜o Paulo, which follows the
guidelines of the Helsinki Declaration of 1975, and all subjects
in this study signed an informed consent form.
Clinical Evaluation. The following clinical features were
evaluated: age of onset, consanguinity, family history,
maximum motor ability (ambulant, ambulant with aid, or
confined to a wheel-chair), calf pseudo-hypertrophy, tiptoe
gait pattern (Achilles tendon shortening), muscle strength,
and the range of motion (ROM) of nine joints (to identify
tendon contractures). The serum CK levels and the presence
of cardiomyopathies, as determined by electrocardiography
and echodoppler, were also evaluated.
Muscle strength was determined according to the Medical
Research Council (MRC) scale, which ranges from 0 to 5. On
this scale, grade 5 is considered normal strength; grade 4
signifies that the patient can complete resisted movements
but does not have normal strength; grade 3 represents the
ability to complete movements against gravity only; in
grade 2 there is movement but not against gravity; grade 1
represents contraction without movement; and grade 0
denotes an absence of muscle contraction. The MRC scale
was applied to evaluate the muscle groups involved in
essential movements because all of the patients included in
the present study were in a chronic stage of the disease,
which posed difficulties in assessing individual muscle
strength. The muscles involved in the following movements
were evaluated: flexion and extension of the shoulders,
elbows, wrists, fingers, thumbs, hips, knees, ankles, and
toes; specific movements of each joint, such as shoulder and
hip adduction, abduction, internal rotation and external
rotation, shoulder elevation, forearm pronation and supina-
tion, wrist ulnar deviation and radial deviation, finger
interosseous, thumb opponency, and ankle inversion and
eversion.
To determine the presence of contractures, the patients
were given a score of complete or incomplete ROM for each
joint, and each individual joint and the percentage of
compromised joints were considered. The joints that were
evaluated for contractures were also evaluated for muscle
strength.
Muscle Biopsy. Muscle biopsies were obtained from
the brachial biceps of all patients using local anesthesia
in the operating room of HC-FMUSP. The samples were
frozen in liquid nitrogen, and 6-mm thick sequential slices
were collected on a cryostat. Routine histological and his-
tochemical staining was conducted as described in detail by
Dubowitz (1985).23
Immunohistochemistry. Specific antibodies against the
sarcoglycans were used to identify the pattern of staining
of this protein complex. Primary antibodies against the
following proteins were used: dystrophin carboxy terminus,
amino terminus, and rod domain (Novocastra, Dy8/6C5,
Dy10/12B2 and Dy4/6D3, respectively), diluted 1/1000; a-
sarcoglycan (Novocastra, Ad1/20A6), diluted 1/100; b-
sarcoglycan (Novocastra, bSarc/5B1), diluted 1/100; c-
sarcoglycan (Novocastra, 35DAG/21B5), diluted 1/100;
and d-sarcoglycan (Novocastra, dSarc3/12CI), diluted 1/
100. The details of the immunohistochemical methods have
been previously described by Ferreira et al. (2005).25 The
sections were classified according to the intensity of the
staining of the sarcolemma as follows: positive staining
(complete staining of all fibers), patchy staining (partial or
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incomplete staining of most fibers) or negative staining
(absence of staining of cell membrane). The samples with
the lowest or absent immunoreactivity were classified as SG
deficient, as shown in Figure 1. Examples of immunostained
muscle biopsy samples from patients included in this series
are presented in Figure 2.
Statistical Analyses. The data are expressed as the mean
¡ SEM. The Kruskal-Wallis test was used to identify
differences among the groups in the non-parametric clinical
data. Pearson’s chi-square test was also employed to test for
associations between components of the clinical data. A one-
way analysis of variance (ANOVA) with Tukey’s post hoc
test (Unequal N HSD) was applied after using Tukey’s test
to record outliers and verify the differences, the power of
these differences and the size effects on muscle strength.
RESULTS
The patients were divided into the following groups
according to the immunohistochemical staining patterns: a-
sarcoglycanopathy (a-SGP) (n = 16), c-sarcoglycanopathy (c-
SGP) (n = 5) and non-SGP. The patients were classified as
non-SGP when the staining for all four sarcoglycans was
positive (n = 23). Only one patient was diagnosed as having
a b-sarcoglycanopathy, and this patient was excluded so as
not to bias the results. The immunohistochemical character-
istics of each patient are shown in Figure 1, and the data
collected from the clinical evaluations of the patients
included in this study are shown in Table 1.
Differences in percentage of patients presenting with
a tiptoe gait pattern and calf pseudo-hypertrophy were
detected among the groups. The Kruskal-Wallis test revealed
a significant difference in the percentage of patients present-
ing with a tiptoe gait pattern between the a-SGP and c-SGP
groups (p=0.03) (Figure 3) and in the percentage of patients
with calf pseudo-hypertrophy between the a-SGP and non-
SGP groups (p= 0.02) (Figure 3). The maximum motor ability
of the groups tended to vary.While 37.5% of the patients with
an a-SG deficiency were confined to a wheelchair, only 12%
of the patients with non-SGP and none of the c-SG patients
were wheelchair bound (Figure 3).
In general, the patients presented with symmetrical
alterations in muscle strength and contractures with some
exceptions due to falls or injuries affecting one side more
than the other. Muscle weakness was more pronounced in
the proximal than in the distal muscles as expected,7 and the
flexor muscles of these patients were found to be more
affected than the extensor muscles. The one-way ANOVA
analysis for the comparison of muscle strength per seg-
ment showed significant differences among the groups
(F(26.22) = 4.4; p= 0.0004). This analysis was highly signifi-
cant (a= 0.99), and the partial eta squared (g2) value was
equal to 0.84, indicating that 84% of the differences found
were due to the diagnosis. The post hoc test (Tukey -
Unequal N HSD) revealed some significant differences in
the muscle strengths of the upper and lower limbs among
the groups as depicted in Figure 4.
The joints with decreased ROM, however, showed no
characteristic contracture patterns among the three groups
analyzed, even after comparing patients within the same
family. Furthermore, no correlations between joint contrac-
tures and muscle strength were found.
DISCUSSION
The present immunohistochemical study in a cohort of
adult LGMD patients allowed us to classify 35% of cases as a-
SGP, 12% as c-SGP, 2% as b-SGP and 51% as non-SGP (in
which no deficiency in any of the four SG proteins was
found). All four SGPs appear to be prevalent in Brazil;
however, d-SGP is the least common form of autosomal
recessive LGMD in Brazil26 and is equally rare world-
wide.27,28 Accordingly, d-SGP was not detected in the present
cohort; the proportion of a-SGP and c-SGP in our cohort was
similar to the proportion found in a previous study.29
Phenotypic differences were identified among the a-SGP,
c-SGP and non-SGP groups. A tiptoe gait pattern was more
frequent in the a-SGP group than in the other groups. The
high frequency of this pattern may be due to the marked
presence of contractures in the a-SGP subtype,7 including
contractures of the Achilles tendon, which lead to the tiptoe
gait pattern. Also, patients classified as a-SGP in the
present cohort presented with more severe muscle weak-
ness and were more frequently confined to a wheelchair
than the other patients. In primary a-SGP, a-SG is the most
severely reduced protein, although there are also deficien-
cies of the other three SGs.24,28-32 However, the spectrum of
protein deficiency may vary from total absence to partial
reduction of this protein with normal staining for the other
SGs.32,33
In the present study, patients classified as c-SGP had
mild phenotype with remarkably preserved muscle
strength; none of them was confined to a wheelchair or
presented with a tiptoe gait pattern or calf pseudo-
hypertrophy. These findings corroborate previous reports
showing that c-SGP has a mild phenotype despite the
complete absence of c-SG and a decrease in the other three
SGs.21,28,33-35 However, in contrast to the present findings,
some studies have reported that the early loss of
ambulation, calf hypertrophy, contractures of the
Achilles tendon, lumbar lordosis, scapular winging, and
weak dorsal thigh and neck muscles are common clinical
features of c-SGP.36
Figure 1 - Patterns of immunohistochemical findings in the non-
SGP, a-SGP, c-SGP, and b-SGP groups. Non-SGP: positive staining
for all four of the sarcoglycans; a-SGP: a-sarcoglycanopathy; c-
SGP: c-sarcoglycanopathy; b-SGP: b-sarcoglycanopathy.
CLINICS 2011;66(10):1713-1719 Phenotype of Sarcoglycanopathies
Ferreira AFB et al.
1715
Figure 2 - Immunohistochemical preparations for alpha, gamma, beta and delta sarcoglycans (a-, c-, b- and d-SG, respectively). (A) A
representative non-SGP case showing positive reactions for all four SGs; (B) a representative case of a-SGP showing no expression of a-
SG and positive reactions for the remaining SGs; (C) a representative case classified as a-SGP showing patchy expression of all four SGs
with lower expression of a-SG; and (D) a representative case of c-SGP showing a negative reaction for c-SG and positive staining for the
other three SGs. 200x magnification. SG: sarcoglycan; SGP: sarcoglycanopathy.
Table 1 - Demographic and clinical data collected from the patients.
Groups
non-SGP a-SGP c-SGP
n 23 16 5
Predominant sex M (54.2%) M (62.5%) F (60%)
Age (mean¡SD) 32.9 (¡13.9) 33.8 (¡16) 43.4 (¡17.1)
Age of Onset (mean¡SD) 18.3 (¡11.1) 17.3 (¡13) 29.3 (¡20.1)
Consanguinity 25% 37.5% 80%
Family history 58.3% 56.3% 60%
Cardiomyopathy 26% 25% 40%
CK nl – 50x 2 – 36x nl – 17x
Tiptoe gait pattern 54.6% 75% 0%
Maximum motor ability A (77.3%) A (56.3%) A (100%)
Calf pseudo-hypertrophy 77.3% 43.8% 0%
% of joints with affected ROM 43.1% (¡13.5) 55% (¡31.3) 37% (¡23.5)
non-SGP: positive staining for all sarcoglycans; a-SGP: a-sarcoglycanopathy; c-SGP: c-sarcoglycanopathy; n: number of patients; CK: range of fold increase
in serum creatine kinase, A: ambulant; ROM: range of motion; nl: normal.
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Similar to a-SGP, studies on c-SGP have described a
heterogeneous phenotype. Nonetheless, the clinical varia-
tions from mild to severe disease have been correlated with
the residual amount of c-SG.33,37 Although the parameters
governing the phenotype/genotype correlation remain
unclear, a linear association has been described between
the degree of protein deficiency and the onset of symp-
toms; a total absence of SGs is associated with an earlier
mean age at disease onset than is observed with partial
deficiencies.22
In the present cohort of patients, the patient presenting
with a deficiency in all four SGs was classified as having
a-SGP, as previously reported by others.24,28-32 However,
this lack of all four SGs has also been described in a
case confirmed to be c-SGP by molecular testing.29
Nevertheless, the results and statistical analyses were not
affected by the classification of this case as either a-SGP or
c-SGP.
The non-SGP group, which showed no immunohisto-
chemical alterations in any of the four SGs, may include
patients harboring either missense mutations in an SG gene
(with no alterations in protein expression) or forms of
LGMD other than SG deficiency. Therefore, patients with
different etiologies were included in this group, which
made the analysis difficult. However, the positive expres-
sion of all four SGs excludes the presence of null mutations
in the SG genes in this group; this type of mutation leads to
a more predictable, uniform and severe phenotype with
Figure 3 - Histograms illustrating the clinical findings. First, the percentage of patients in each group presenting with a tiptoe gait
pattern are shown. The Kruskal-Wallis test showed a significant difference between the a-SGP and c-SGP groups (p=0.03). Second, the
percentage of patients in each group with calf pseudo-hypertrophy is shown. The Kruskal-Wallis test showed a significant difference
between the a-SGP and c-SGP groups (p=0.02). Third, the maximum motor ability of the groups is shown. 37.5% of the patients with
an a-SG deficiency were confined to a wheelchair, while only 12% of the patients with a c-SG deficiency and none of the non-SGP
patients were wheelchair bound. non-SGP: positive staining for all sarcoglycans; a-SGP: a-sarcoglycanopathy; c-SGP: c-sarcoglycano-
pathy; A: ambulant; AA: ambulant with aid; W: confined to a wheelchair.
Figure 4 - Graphs illustrating the differences found among the three groups from the comparative analysis of the muscle strength
scores of the shoulders and upper limbs (A) and of the hips and lower limbs (B) (* p,0.05; ** p,0.01; *** p,0.001). non-SGP: positive
staining for all sarcoglycans; a-SGP: a-sarcoglycanopathy; c-SGP: c-sarcoglycanopathy.
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decreased expression levels of the protein encoded by the
affected gene.22 The higher frequency of calf pseudo-
hypertrophy observed in this group, however, might point
to some other form of LGMD, such as calpainopathy, in
which calf pseudo-hypertrophy is common.7
Molecular testing is fundamental for the establishment
of the final diagnosis of LGMD and will certainly be
mandatory when a gene-based treatment becomes available.
However, considering the continuous increase in LGMD
types caused by alterations in different proteins of the
muscular system, it is important to find clinical parameters
and accessible laboratory tools to prioritize the molecular
characterization of LGMD. Efforts have been made to
improve the differential diagnosis by comparing mutations
to immunohistochemical findings from SGP patients29 or by
comparing general muscle strength to other laboratory data
obtained from LGMD patients.38 Nonetheless, detailed
muscular evaluations must be correlated with laboratory
findings to identify clinical markers specific to each
situation.
To this end, the present results show that a systematic
clinical evaluation, together with immunohistochemical
staining of muscle samples, enabled the characterization of
LGMD patients. Applying this strategy to a larger number
of patients may further refine these tools and help to
determine the cost/benefit ratio of the molecular diagnosis.
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